Technology | February 11, 2013

New Competitor Enters IVUS Market

Silicon Valley Medical Instruments Inc.  HD-IVUS FDA Clearance

February 11, 2013 — Silicon Valley Medical Instruments Inc. (SVMI) was granted 510(k) market clearance from the U.S. Food and Drug Administration (FDA) in January for its HD-IVUS ultrasound imaging system.

The HD-IVUS ultrasound imaging system is a minimally invasive intravascular ultrasound diagnostic imaging tool, used in conjunction with an intravascular ultrasound catheter. The system is a medical device for use by or on the order of a physician. The HD-IVUS is comprised of a system console with a touchscreen monitor, roll stand or bed-rail swing arm mount, patient interface module (PIM), power supply, and an intravascular ultrasound catheter [510(k)-cleared and  sold separately].

The catheter emits sound energy from a transducer at the distal tip of the catheter, which is guided into the coronary arteries of the heart. Sound waves that reflect from the inner vascular tissues are received by the transducer and sent to the system console where a high-resolution, cross-sectional image is displayed in real time. The technique provides for in vivo visualization of the coronary artery lumen, coronary artery wall morphology, and devices (such as stents) at or near the surface of the coronary artery wall.

The system console receives, processes, displays and records ultrasound image data from the transducer in the Kodama HD-IVUS catheter. The IVUS images are displayed on a high-resolution, 19-inch, flat-panel, touchscreen monitor. The monitor serves as a graphical user interface (GUI) for operating the system. All system information and controls are located on the touchscreen monitor.

The HD-IVUS system also has internal storage for patient studies. Each study can contain data in the form of loops or stills. Study data is saved in digital imaging and communications in medicine (DICOM) format and can be exported to DVID, using the integrated DVD drive, or to a USIB storage device, using one of the four USB ports.

For more information: www.svmii.com

Related Content

Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Overlay Init